Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

50
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
50
Metastasis02:30

Metastasis

5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer.

Cells·2026
Same author

Invited Commentary: Building Bridges: A National Mentorship Network as a Model for Surgical Education.

Journal of the American College of Surgeons·2026
Same author

From Description to Action: A Roadmap for Dismantling Cancer Disparities in Surgical Oncology.

Annals of surgical oncology·2026
Same author

Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial.

Molecular therapy. Oncology·2026
Same author

Viewing Inflammation and Immunoregulation Under the Calpain System Lens.

Cells·2025
Same author

Now More than Ever.

American journal of surgery·2025

Related Experiment Video

Updated: Jul 27, 2025

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.5K

Immunometabolic reprogramming, another cancer hallmark.

Vijay Kumar1, John H Stewart1,2

  • 1Department of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Science Center (LSUHSC), New Orleans, LA, United States.

Frontiers in Immunology
|June 5, 2023
PubMed
Summary
This summary is machine-generated.

Cancer progression involves inflammation-driven immune cell metabolism changes. Targeting tumor immunometabolic reprogramming offers a new path for cancer immunotherapy, linking inflammation and metastasis.

Keywords:
TIMETMEcancerimmunityimmunometabolic reprogrammingimmunometabolisminflammation

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

456
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.4K

Related Experiment Videos

Last Updated: Jul 27, 2025

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.5K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

456
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.4K

Area of Science:

  • Oncology
  • Immunology
  • Metabolic research

Background:

  • Cancer develops through acquired abnormalities in key biological processes, known as the six hallmarks of cancer.
  • Non-resolving inflammation can disrupt immune cell metabolism, driving cancer progression and metastasis.

Purpose of the Study:

  • To delineate immunometabolic reprogramming as a critical hallmark of cancer.
  • To link chronic inflammation and immunosuppression to cancer growth and metastasis.

Main Methods:

  • Review and synthesis of current literature on molecular carcinogenesis, inflammation, and cancer metabolism.
  • Conceptual framework development linking immunometabolic reprogramming to cancer hallmarks.

Main Results:

  • Immunometabolic reprogramming is identified as a critical, unifying hallmark of cancer.
  • Chronic inflammation and immunosuppression are mechanistically linked to cancer growth and metastasis via metabolic dysregulation.

Conclusions:

  • Targeting tumor immunometabolic reprogramming presents a promising strategy for novel cancer immunotherapies.
  • Understanding and manipulating cancer cell metabolism in the context of inflammation and immunity is crucial for effective treatment design.